A2A adenosine receptor deletion is protective in a mouse model of Tauopathy

Molecular Psychiatry

Volumn 21, Issue 1, 2016, Pages 97-107

  Laurent, C ^a,b   Burnouf, S ^a,b   Ferry, B ^c   Batalha, V L ^d   Coelho, J E ^d   Baqi, Y ^e,f   Malik, E ^e   Mariciniak, E ^a,b   Parrot, S ^c,g   Van Der Jeugd, A ^h   Faivre, E ^a,b   Flaten, V ^a,b   Ledent, C ⁱ   D'Hooge, R ^h   Sergeant, N ^a,b,j   Hamdane, M ^a,b,j   Humez, S ^a,b   Muller C E ^e   Lopes, L V ^d   Buee L ^a,b,j   Blum, D ^a,b,j   more..

^a UNIV LILLE   (France)

^b JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^c LYON NEUROSCIENCE RESEARCH CENTER   (France)

^d INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^e UNIVERSITY OF BONN   (Germany)

^f SULTAN QABOOS UNIVERSITY   (Oman)

^g NeuroDialyTics   (France)

^h UNIVERSITY OF LEUVEN   (Belgium)

ⁱ UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^j LILLE UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ADENOSINE A2 RECEPTOR; ADENOSINE A2 RECEPTOR ANTAGONIST; CYCLIN DEPENDENT KINASE 5; GABA TRANSPORTER 1; GABA TRANSPORTER 2; GABA TRANSPORTER 3; GLUTAMIC ACID; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MSX 3; NEUROTRANSMITTER; RANTES; TAU PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ADENOSINE A2A RECEPTOR; MAPT PROTEIN, HUMAN; MESSENGER RNA; MSX 3 COMPOUND; XANTHINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FUNCTIONAL DISEASE; GENE DELETION; GENE EXPRESSION; GENOTYPE; HIPPOCAMPAL PLASTICITY; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LONG TERM DEPRESSION; MALE; MEMORY; MEMORY DISORDER; MORRIS WATER MAZE TEST; MOTOR PERFORMANCE; MOUSE; NERVOUS SYSTEM FUNCTION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OPEN FIELD TEST; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; ROTAROD TEST; SPATIAL LEARNING; SPATIAL MEMORY; TAUOPATHY; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION; WEIGHT GAIN; Y-MAZE TEST; ALZHEIMER DISEASE; ANIMAL; COGNITION DISORDERS; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TAUOPATHIES; TISSUE CULTURE TECHNIQUE; TRANSGENIC MOUSE;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ALZHEIMER DISEASE; ANIMALS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HIPPOCAMPUS; HUMANS; LONG-TERM SYNAPTIC DEPRESSION; MICE, TRANSGENIC; PHOSPHORYLATION; RECEPTOR, ADENOSINE A2A; RNA, MESSENGER; TAU PROTEINS; TAUOPATHIES; TISSUE CULTURE TECHNIQUES; XANTHINES;

EID: 84951905228     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2014.151     Document Type: Article

References (64)

1. Flaten V, Laurent C, Coelho J, Sandau U, Batalha VL, Burnouf S et al. From epidemiology to pathophysiology: what about caffeine in Alzheimer's disease? Biochem Soc Trans 2014; 42: 587-592.
2. Arendash GW, Schleif W, Rezai-Zadeh K, Jackson EK, Zacharia LC, Cracchiolo JR et al. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production. Neuroscience 2006; 142: 941-952.
3. Laurent C, Eddarkaoui S, Derisbourg M, Leboucher A, Demeyer D, Carrier S et al. Beneficial effects of caffeine in a transgenic model of Alzheimer's disease-like tau pathology. Neurobiol Aging 2014; 35: 2079-2090.
4. Muller CE, Jacobson KA. Xanthines as adenosine receptor antagonists. Handbook of Experimental Pharmacology, 2011, pp 151-199.
5. Blum D, Hourez R, Galas MC, Popoli P, Schiffmann SN. Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics. Lancet Neurol 2003; 2: 366-374.
6. Popoli P, Blum D, Martire A, Ledent C, Ceruti S, Abbracchio MP. Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease. Progr Neurobiol 2007; 81: 331-348.
7. Sebastiao AM, Ribeiro FF, Ribeiro JA. From A1 to A3 en passant through A(2A) receptors in the hippocampus: pharmacological implications. CNS Neurol Disorders Drug Targets 2012; 11: 652-663.
8. Wei CJ, Li W, Chen JF. Normal and abnormal functions of adenosine receptors in the central nervous system revealed by genetic knockout studies. Biochim Biophys Acta 2011; 1808: 1358-1379.
9. Chen JF, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 2001; 21: RC143.
10. Kachroo A, Schwarzschild MA. Adenosine A2A receptor gene disruption protects in an alpha-synuclein model of Parkinson's disease. Ann Neurol 2012; 71: 278-282.
11. Canas PM, Porciuncula LO, Cunha GM, Silva CG, Machado NJ, Oliveira JM et al. Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway. J Neurosci 2009; 29: 14741-14751.
12. Duyckaerts C, Bennecib M, Grignon Y, Uchihara T, He Y, Piette F et al. Modeling the relation between neurofibrillary tangles and intellectual status. Neurobiol Aging 1997; 18: 267-273.
13. Grober E, Dickson D, Sliwinski MJ, Buschke H, Katz M, Crystal H et al. Memory and mental status correlates of modified Braak staging. Neurobiol Aging 1999; 20: 573-579.
14. Burnouf S, Belarbi K, Troquier L, Derisbourg M, Demeyer D, Leboucher A et al. Hippocampal BDNF expression in a tau transgenic mouse model. Curr Alzheimer Res 2012; 9: 406-410.
15. Van der Jeugd A, Vermaercke B, Derisbourg M, Lo AC, Hamdane M, Blum D et al. Progressive age-related cognitive decline in tau mice. J Alzheimer's Dis 2013; 37: 777-788.
16. Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, El Yacoubi M, Vanderhaeghen JJ et al. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 1997; 388: 674-678.
17. Burnouf S, Martire A, Derisbourg M, Laurent C, Belarbi K, Leboucher A et al. NMDA receptor dysfunction contributes to impaired brain-derived neurotrophic factorinduced facilitation of hippocampal synaptic transmission in a Tau transgenic model. Aging Cell 2013; 12: 11-23.
18. Troquier L, Caillierez R, Burnouf S, Fernandez-Gomez FJ, Grosjean ME, Zommer N et al. Targeting phospho-Ser422 by active Tau immunotherapy in the THY-Tau22 mouse model: a suitable therapeutic approach. Current Alzheimer Research 2012; 9: 397-405.
19. Hockemeyer J, Burbiel JC, Müller CE. Multigram-scale syntheses, stability, and photoreactions of A2A adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson's disease. J Org Chem 2004; 69: 3308-3318.
20. Collins LE, Galtieri DJ, Brennum LT, Sager TN, Hockemeyer J, Müller CE et al. Oral tremor induced by the muscarinic agonist pilocarpine is suppressed by the adenosine A2A antagonists MSX-3 and SCH58261, but not the adenosine A1 antagonist DPCPX. Pharmacol Biochem Behav 2010; 94: 561-569.
21. Belarbi K, Burnouf S, Fernandez-Gomez FJ, Laurent C, Lestavel S, Figeac M et al. Beneficial effects of exercise in a transgenic mouse model of Alzheimer's disease like Tau pathology. Neurobiol Dis 2011; 43: 486-494.
22. Planel E, Richter KE, Nolan CE, Finley JE, Liu L, Wen Y et al. Anesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia. J Neurosci 2007; 27: 3090-3097.
23. Fernandez-Gomez FJ, Jumeau F, Derisbourg M, Burnouf S, Tran H, Eddarkaoui S et al. Consensus brain-derived protein, extraction protocol for the study of human and murine brain proteome using both 2D-DIGE and mini 2DE immunoblotting. J Vis Exp advance online publication, 10 April 2014; doi:10.3791/51339.
24. Leboucher A, Laurent C, Fernandez-Gomez FJ, Burnouf S, Troquier L, Eddarkaoui S et al. Detrimental effects of diet-induced obesity on tau pathology are independent of insulin resistance in tau transgenic mice. Diabetes 2013; 62: 1681-1688.
25. Batalha VL, Pego JM, Fontinha BM, Costenla AR, Valadas JS, Baqi Y et al. Adenosine A(2A) receptor blockade reverts hippocampal stress-induced deficits and restores corticosterone circadian oscillation. Mol Psychiatry 2013; 18: 320-331.
26. Van der Jeugd A, Ahmed T, Burnouf S, Belarbi K, Hamdame M, Grosjean ME et al. Hippocampal tauopathy in tau transgenic mice coincides with impaired hippocampus-dependent learning and memory, and attenuated late-phase longterm depression of synaptic transmission. Neurobiol Learn Memory 2011; 95: 296-304.
27. Bert L, Favale D, Jego G, Greve P, Guilloux JP, Guiard BP et al. Rapid and precise method to locate microdialysis probe implantation in the rodent brain. J Neurosci Methods 2004; 140: 53-57.
28. Sauvinet V, Parrot S, Benturquia N, Bravo-Moraton E, Renaud B, Denoroy L. In vivo simultaneous monitoring of gamma-aminobutyric acid, glutamate, and L-aspartate using brain microdialysis and capillary electrophoresis with laser-induced fluorescence detection: analytical developments and in vitro/in vivo validations. Electrophoresis 2003; 24: 3187-3196.
29. Sergeant N, Bretteville A, Hamdane M, Caillet-Boudin ML, Grognet P, Bombois S et al. Biochemistry of Tau in Alzheimer's disease and related neurological disorders. Expert Rev Proteomics 2008; 5: 207-224.
30. Zilka N, Kovacech B, Barath P, Kontsekova E, Novak M. The self-perpetuating tau truncation circle. Biochem Soc Trans 2012; 40: 681-686.
31. Bellucci A, Westwood AJ, Ingram E, Casamenti F, Goedert M, Spillantini MG. Induction of inflammatory mediators and microglial activation in mice transgenic for mutant human P301S tau protein. Am J Pathol 2004; 165: 1643-1652.
32. Lee DC, Rizer J, Selenica ML, Reid P, Kraft C, Johnson A et al. LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. J Neuroinflamm 2010; 7: 56.
33. Bardou I, Brothers HM, Kaercher RM, Hopp SC, Wenk GL. Differential effects of duration and age on the consequences of neuroinflammation in the hippocampus. Neurobiol Aging 2013; 34: 2293-2301.
34. Rebola N, Simoes AP, Canas PM, Tome AR, Andrade GM, Barry CE et al. Adenosine A2A receptors control neuroinflammation and consequent hippocampal neuronal dysfunction. J Neurochem 2011; 117: 100-111.
35. Matos M, Augusto E, Agostinho P, Cunha RA, Chen JF. Antagonistic interaction between adenosine A2A receptors and Na+/K+-ATPase-alpha2 controlling glutamate uptake in astrocytes. J Neurosci 2013; 33: 18492-18502.
36. Cristovao-Ferreira S, Navarro G, Brugarolas M, Perez-Capote K, Vaz SH, Fattorini G et al. A1R-A2AR heteromers coupled to Gs and G i/0 proteins modulate GABA transport into astrocytes. Purinergic Signal 2013; 9: 433-449.
37. Albasanz JL, Perez S, Barrachina M, Ferrer I, Martin M. Up-regulation of adenosine receptors in the frontal cortex in Alzheimer's disease. Brain Pathol 2008; 18: 211-219.
38. Zhou SJ, Zhu ME, Shu D, Du XP, Song XH, Wang XT et al. Preferential enhancement of working memory in mice lacking adenosine A(2A) receptors. Brain Res 2009; 1303: 74-83.
39. Wei CJ, Singer P, Coelho J, Boison D, Feldon J, Yee BK et al. Selective inactivation of adenosine A(2A) receptors in striatal neurons enhances working memory and reversal learning. Learn Memory 2011; 18: 459-474.
40. Leite MR, Wilhelm EA, Jesse CR, Brandao R, Nogueira CW. Protective effect of caffeine and a selective A2A receptor antagonist on impairment of memory and oxidative stress of aged rats. Exp Gerontol 2011; 46: 309-315.
41. Ning YL, Yang N, Chen X, Xiong RP, Zhang XZ, Li P et al. Adenosine A2A receptor deficiency alleviates blast-induced cognitive dysfunction. J Cerebr Blood Flow Metab 2013; 33: 1789-1798.
42. Le Freche H, Brouillette J, Fernandez-Gomez FJ, Patin P, Caillierez R, Zommer N et al. Tau phosphorylation and sevoflurane anesthesia: an association to postoperative cognitive impairment. Anesthesiology 2012; 116: 779-787.
43. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005; 309: 476-481.
44. Gorlovoy P, Larionov S, Pham TT, Neumann H. Accumulation of tau induced in neurites by microglial proinflammatory mediators. FASEB J 2009; 23: 2502-2513.
45. Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM. Lipopolysaccharideinduced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci 2005; 25: 8843-8853.
46. Orr AG, Orr AL, Li XJ, Gross RE, Traynelis SF. Adenosine A(2A) receptor mediates microglial process retraction. Nature Neurosci 2009; 12: 872-878.
47. Dai SS, Zhou YG, Li W, An JH, Li P, Yang N et al. Local glutamate level dictates adenosine A2A receptor regulation of neuroinflammation and traumatic brain injury. J Neurosci 2010; 30: 5802-5810.
48. Yu L, Shen HY, Coelho JE, Araujo IM, Huang QY, Day YJ et al. Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann Neurol 2008; 63: 338-346.
49. Pascual O, Casper KB, Kubera C, Zhang J, Revilla-Sanchez R, Sul JY et al. Astrocytic purinergic signaling coordinates synaptic networks. Science 2005; 310: 113-116.
50. Boison D. Adenosine dysfunction in epilepsy. Glia 2012; 60: 1234-1243.
51. Studer FE, Fedele DE, Marowsky A, Schwerdel C, Wernli K, Vogt K et al. Shift of adenosine kinase expression from neurons to astrocytes during postnatal development suggests dual functionality of the enzyme. Neuroscience 2006; 142: 125-137.
52. Shen HY, Singer P, Lytle N, Wei CJ, Lan JQ, Williams-Karnesky RL et al. Adenosine augmentation ameliorates psychotic and cognitive endophenotypes of schizophrenia. J Clin Invest 2012; 122: 2567-2577.
53. Yee BK, Singer P, Chen JF, Feldon J, Boison D. Transgenic overexpression of adenosine kinase in brain leads to multiple learning impairments and altered sensitivity to psychomimetic drugs. Eur J Neurosci 2007; 26: 3237-3252.
54. Matos M, Augusto E, Machado NJ, dos Santos-Rodrigues A, Cunha RA, Agostinho P. Astrocytic adenosine A2A receptors control the amyloid-? peptide-induced decrease of glutamate uptake. J Alzheimers Dis 2012; 31: 555-567.
55. Cristovao-Ferreira S, Vaz SH, Ribeiro JA, Sebastiao AM. Adenosine A2A receptors enhance GABA transport into nerve terminals by restraining PKC inhibition of GAT-1. J Neurochem 2009; 109: 336-347.
56. Xu XH, Zheng XX, Zhou Q, Li H. Inhibition of excitatory amino acid efflux contributes to protective effects of puerarin against cerebral ischemia in rats. Biomed Environ Sci 2007; 20: 336-342.
57. Dong X, Zhang D, Zhang L, Li W, Meng X. Osthole improves synaptic plasticity in the hippocampus and cognitive function of Alzheimers disease rats via regulating glutamate. Neural Regen Res 2012; 7: 2325-2332.
58. Luo J, Min S, Wei K, Li P, Dong J, Liu YF. Propofol protects against impairment of learning-memory and imbalance of hippocampal Glu/GABA induced by electroconvulsive shock in depressed rats. J Anesth 2011; 25: 657-665.
59. Altinbilek B, Manahan-Vaughan D. Antagonism of group III metabotropic glutamate receptors results in impairment of LTD but not LTP in the hippocampal CA1 region, and prevents long-term spatial memory. Eur J Neurosci 2007; 26: 1166-1172.
60. Dong Z, Bai Y, Wu X, Li H, Gong B, Howland JG et al. Hippocampal long-term depression mediates spatial reversal learning in the Morris water maze. Neuropharmacology 2013; 64: 65-73.
61. Rodrigues TM, Jeronimo-Santos A, Sebastiao AM, Diogenes MJ. Adenosine A(2A) receptors as novel upstream regulators of BDNF-mediated attenuation of hippocampal long-term depression (LTD). Neuropharmacology 2014; 79: 389-398.
62. Min SS, Quan HY, Ma J, Han JS, Jeon BH, Seol GH. Chronic brain inflammation impairs two forms of long-term potentiation in the rat hippocampal CA1 area. Neurosci Lett 2009; 456: 20-24.
63. Peineau S, Nicolas CS, Bortolotto ZA, Bhat RV, Ryves WJ, Harwood AJ et al. A systematic investigation of the protein kinases involved in NMDA receptordependent LTD: evidence for a role of GSK-3 but not other serine/threonine kinases. Mol Brain 2009; 2: 22.
64. Ahmed T, Blum D, Burnouf S, Demeyer D, Bu?e-Scherrer V, D'Hooge R et al. Inhibition of GSK3? and activation of PP2A rescue defects in NMDAR-mediated late phase LTD in a Tau transgenic mouse model. Neurobiology of Aging (in press).